Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.49B | $1.62B | $1.89B | $2.16B | $2.36B | $3.09B | $3.66B | $3.83B | $4.07B | $4.27B |
| Revenue growth | — | 8.8% | 16.8% | 14.3% | 9.3% | 30.9% | 18.3% | 4.8% | 6.1% | 4.9% |
| Operating income | $592M | $529M | $615M | $532M | $378M | $170M | -$65.5M | $579M | $717M | -$430M |
| Operating margin | 39.8% | 32.7% | 32.5% | 24.6% | 16.0% | 5.5% | -1.8% | 15.1% | 17.6% | -10.1% |
| Net income | $397M | $488M | $447M | $523M | $239M | -$330M | -$224M | $415M | $560M | -$356M |
| Net margin | 26.7% | 30.1% | 23.6% | 24.2% | 10.1% | -10.7% | -6.1% | 10.8% | 13.8% | -8.3% |
| EPS (diluted) | $6.41 | $7.96 | $7.30 | $9.09 | $4.22 | -$5.52 | -$3.58 | $6.10 | $8.65 | -$5.84 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $592M | $693M | $799M | $776M | $900M | $779M | $1.27B | $1.09B | $1.40B | $1.36B |
| Capital expenditures | $9.69M | $28.9M | $20.4M | $40.1M | $15.0M | $27.6M | $29.0M | $24.0M | $38.1M | $58.8M |
| Free cash flow | $583M | $664M | $779M | $736M | $885M | $751M | $1.24B | $1.07B | $1.36B | $1.30B |
| Share buybacks | $278M | $98.8M | $524M | $301M | $147M | $0.00 | $54.0K | $270M | $311M | $125M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $366M | $386M | $310M | $637M | $1.06B | $591M | $881M | $1.51B | $2.41B | $1.39B |
| Total assets | $4.80B | $5.12B | $5.20B | $5.54B | $6.54B | $12.3B | $10.8B | $11.4B | $12.0B | $11.7B |
| Long-term debt | $1.99B | $1.54B | $1.56B | $1.57B | $1.85B | $6.02B | $5.69B | $5.11B | $6.08B | $4.33B |
| Shareholders' equity | $1.88B | $2.71B | $2.76B | $3.11B | $3.66B | $3.97B | $3.09B | $3.74B | $4.09B | $4.32B |
| Retained earnings | $529M | $918M | $841M | $1.07B | $1.16B | $830M | $734M | $879M | $1.13B | $646M |
| Shares (wtd avg diluted) | 61.9M | 61.3M | 61.2M | 57.5M | 56.5M | 59.7M | 62.5M | 72.1M | 66.0M | 61.0M |
Every figure is extracted from Jazz Pharmaceuticals plc’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.